Runx2 induces acute myeloid leukemia in cooperation with Cbfp-SMMHC in mice

Blood

Volumn 113, Issue 14, 2009, Pages 3323-3332

  Kuo, Ya Huei ^a   Zaidi, Sayyed K ^b   Gornostaeva, Svetlana ^a   Komori, Toshihisa ^c   Stein, Gary S ^b   Castilla, Lucio H ^a,d  

^a Program in Gene Function and Expression   (Japan)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; CELL PROTEIN; COLONY STIMULATING FACTOR RECEPTOR; CORE BINDING FACTOR BETA; CORE BINDING FACTOR BETA SMOOTH MUSCLE MYOSIN HEAVY CHAIN; MYELOPEROXIDASE; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL ASSAY; CELL DIFFERENTIATION; CELL NUCLEUS MATRIX; CONTROLLED STUDY; DNA BINDING; HEMATOPOIETIC STEM CELL; INTRACELLULAR SPACE; LEUKEMOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSPLANTATION;

EID: 65349163429     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-06-162248     Document Type: Article

References (61)

1. Wang S, Wang Q, Crute BE, Melnikova IN, Keller SR, Speck NA. Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol. 1993;13:3324-3339.
2. Ogawa E, Inuzuka M, Maruyama M, et al. Molecular cloning and characterization of PEBP2 beta, the heterodimeric partner of a novel Drosophila runt-related DNA binding protein PEBP2 alpha. Virology. 1993;194:314-331.
3. Tang L, Guo B, Javed A, et al. Crystal structure of the nuclear matrix targeting signal of the transcription factor acute myelogenous leukemia-1/ polyoma enhancer-binding protein 2alphaB/core binding factor alpha2. J Biol Chem. 1999;274: 33580-33586.
4. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321-330.
5. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive he- matopoiesis. Proc Natl Acad Sci USA. 1996;93:3444-3449.
6. Wang Q, Stacy T, Miller JD, et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell. 1996;87:697-708.
7. Yokomizo T, Ogawa M, Osato M, et al. Requirement of Runx1/AML1/ PEBP2alphaB for the generation of haematopoietic cells from endothelial cells. Genes Cells. 2001;6:13-23.
8. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation because of maturational arrest of osteoblasts. Cell. 1997;89:755-764.
9. Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer. 2005;5:376-387.
10. Meyers S, Lenny N, Hiebert SW. The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation. Mol Cell Biol. 1995;15:1974-1982.
11. Castilla LH, Wijmenga C, Wang Q, et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell. 1996;87:687-696.
12. Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood. 1999;93:1817-1824.
13. Harada H, Harada Y,Tanaka H, Kimura A, Inaba T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood. 2003;101:673-680.
14. Christiansen DH, Andersen MK, Pedersen-Bjergaard J, et al. Mutations of AML1 are common intherapy related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood. 2004;104:1474-1481.
15. Tartaglia M, Martinelli S, Cazzaniga G, et al. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood. 2004;104:307-313.
16. Niini T, Kanerva J, Vettenranta K, SaarinenPihkala UM, Knuutila S. AML1 gene amplification: a novel finding in childhood acute lymphoblastic leukemia. Haematologica. 2000;85:362-366.
17. Harewood L, Robinson H, Harris R, et al. Amplification of AML1 on a duplicated chromosome 21 in acute lymphoblastic leukemia: a study of 20 cases. Leukemia. 2003;17:547-553.
18. Roumier C, Fenaux P, Lafage M, Imbert M, Eclache V, Preudhomme C. New mechanisms of AML1 gene alteration in hematological malignancies. Leukemia. 2003;17:9-16.
19. Robinson HM, Broadfield ZJ, Cheung KL, et al. Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome. Leukemia. 2003;17:2249-2250.
20. Andersen MK, Christiansen DH, Pedersen Bjergaard J. Amplification or duplication of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML. Leukemia. 2005;19:197-200.
21. Garcia-Casado Z, Cervera J, Verdeguer A, et al. High-level amplification of the RUNX1 gene in two cases of childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2006;170:171-174.
22. Kirschnerova G, Tothova A, Babusikova O. Amplification of AML1 gene in association with karyotype, age and diagnosis in acute leukemia patients. Neoplasma. 2006;53:150-154.
23. Mikhail FM, Serry KA, Hatem N, et al. AML1 gene over-expression in childhood acute lymphoblastic leukemia. Leukemia. 2002;16:658-668.
24. Stewart M, Terry A, O'Hara M, Cameron E, Onions D, Neil JC. til-1: a novel proviral insertion locus for Moloney murine leukaemia virus in lym- phomas of CD2-myc transgenic mice. J Gen Virol. 1996;77:443-446.
25. Stewart M, Terry A, Hu M, et al. Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc collaborating oncogene. Proc Natl Acad Sci USA. 1997;94:8646-8651.
26. Vaillant F, Blyth K, Terry A, et al. A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with myc. Oncogene. 1999;18:7124-7134.
27. Stewart M, MacKay N, Cameron ER, Neil JC. The common retroviral insertion locus Dsi1 maps 30 kilobases upstream of the P1 promoter of the murine Runx3/Cbfa3/Aml2 gene. J Virol. 2002;76: 4364-4369.
28. Wotton S, Stewart M, Blyth K, et al. Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma. Cancer Res. 2002;62:7181-7185.
29. Li J, Shen H, Himmel KL, et al. Leukaemia disease genes: large-scale cloning and pathway predictions. Nat Genet. 1999;23:348-353.
30. Mikkers H, Allen J, Knipscheer P, et al. High throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet. 2002;32:153-159.
31. Osato M, Ito Y. Increased dosage of the RUNX1/ AML1 gene: athird mode of RUNX leukemia? Crit Rev Eukaryot Gene Expr. 2005;15:217-228.
32. Yanagida M, Osato M, Yamashita N, et al. Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice. Oncogene. 2005;24:4477-4485.
33. Castilla LH, Garrett L, Adya N, et al.The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet. 1999;23:144-146.
34. Kuo YH, Landrette SF, Heilman SA, et al. Cbf beta-SMMHC induces distinct abnormal myeloid progenitors able to develop acute myeloid leukemia. Cancer Cell. 2006;9:57-68.
35. Castilla LH, Perrat P, Martinez NJ, et al. Identification of genes that synergize with Cbfb-MYH11 in the pathogenesis of acute myeloid leukemia. Proc Natl Acad Sci USA. 2004;101:4924-4929.
36. Choi JY, Pratap J, Javed A, et al. Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue-specific differentiation during embryonic development. Proc Natl Acad Sci USA. 2001;98: 8650-8655.
37. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995;269:1427-1429.
38. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 2000;404:193-197.
39. Christensen JL, Weissman IL. Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad Sci U S A. 2001;98:14541-14546.
40. Morrison SJ, Wandycz AM, Hemmati HD, Wright DE, Weissman IL. Identification of a lineage of multipotent hematopoietic progenitors: the long- term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Development. 1997;124:1929-1939.
41. Morrison SJ, Weissman IL. The long-term re- populating subset of hematopoietic stem cells is deterministic and isolatable byphenotype. Immunity. 1994;1:661-673.
42. Young DW, Hassan MQ, Yang XQ, et al. Mitotic retention of gene expression patterns by the cell fate-determining transcription factor Runx2. Proc Natl Acad Sci USA. 2007;104:3189-3194.
43. Nuchprayoon I, Meyers S, Scott LM, Suzow J, Hiebert S, Friedman AD. PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2 beta/CBF beta proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol. 1994;14:5558-5568.
44. Zhang DE, Fujioka K, Hetherington CJ, et al. Identification of a region which directs the monocytic activity of the colony-stimulating factor 1 (macrophage colony-stimulating factor) receptor promoter and binds PEBP2/CBF (AML1). Mol Cell Biol. 1994;14:8085-8095.
45. Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem. 2000;275:651-656.
46. Westendorf JJ, Zaidi SK, Cascino JE, et al. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol. 2002;22:7982- 7992.
47. McCarthy TL, Ji C, Chen Y, et al. Runt domain factor (Runx)-dependent effects on CCAAT/ enhancer-binding protein delta expression and activity in osteoblasts. J Biol Chem. 2000;275:21746-21753.
48. Li Z, Yan J, Matheny CJ, et al. Energetic contribution of residues in the Runx1 Runt domain to DNA binding. J Biol Chem. 2003;278:33088- 33096.
49. Zaidi SK, Sullivan AJ, Medina R, et al. Tyrosine phosphorylation controls Runx2-mediated sub- nuclear targeting of YAP to repress transcription. EMBO J. 2004;23:790-799.
50. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J. 1999;18:2551-2562.
51. Zaidi SK, Javed A, Pratap J, et al. Alterations in intranuclear localization of Runx2 affect biological activity. J Cell Physiol. 2006;209:935-942.
52. Slape C, Hartung H, Lin YW, Bies J, WolffL, Aplan PD. Retroviral insertional mutagenesis identifies genes that collaborate with NUP98HOXD13 during leukemic transformation. Cancer Res. 2007;67:5148-5155.
53. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442:818-822.
54. Stock M, Otto F. Control of RUNX2 isoform expression: the role of promoters and enhancers. J Cell Biochem. 2005;95:506-517.
55. Heilman SA, Kuo YH, Goudswaard CS, Valk PJ, Castilla LH. Cbfbeta reduces Cbfbeta-SMMHC- associated acute myeloid leukemia in mice. Cancer Res. 2006;66:11214-11218.
56. Zaidi SK, Pande S, Pratap J, et al. Runx2 deficiency and defective subnuclear targeting bypass senescence to promote immortalization and tu- morigenic potential. Proc Natl Acad Sci U S A. 2007;104:19861-19866.
57. Vitolo MI, Anglin IE, Mahoney WM Jr, et al. The RUNX2 transcription factor cooperates with the YES- associated protein, YAP65, to promote cell transformation. Cancer Biol Ther. 2007;6:856-863.
58. Jensen ED, Schroeder TM, Bailey J, Gopalakrishnan R, Westendorf JJ. Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J Bone Miner Res. 2008;23:361-372.
59. Peterson LF, Yan M, Zhang DE. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood. 2007;109:4392-4398.
60. Taniuchi I, Osato M, EgawaT, et al. Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell. 2002;111:621-633.
61. Vaillant F, Blyth K, Andrew L, Neil JC, Cameron ER. Enforced expression of Runx2 perturbs T cell development at a stage coincident with beta- selection. J Immunol. 2002;169:2866-2874.